Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S, Patel M, Kurkjian C, Hemphill B, Flores M, Thompson D, Bendell J. Pant S, et al. Cancer Invest. 2017 Aug 9;35(7):463-472. doi: 10.1080/07357907.2017.1337782. Epub 2017 Jun 29. Cancer Invest. 2017. PMID: 28662341 Clinical Trial.
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Zhou X, Pant S, Nemunaitis J, Craig Lockhart A, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargfrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K. Zhou X, et al. Invest New Drugs. 2018 Apr;36(2):248-258. doi: 10.1007/s10637-017-0499-z. Epub 2017 Aug 30. Invest New Drugs. 2018. PMID: 28852909 Free PMC article. Clinical Trial.
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Hong DS, Moore K, Patel M, Grant SC, Burris HA 3rd, William WN Jr, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Hong DS, et al. Clin Cancer Res. 2018 Jul 15;24(14):3263-3272. doi: 10.1158/1078-0432.CCR-17-3347. Epub 2018 Apr 11. Clin Cancer Res. 2018. PMID: 29643063 Free PMC article. Clinical Trial.
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Hong DS, Moore KN, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR. Hong DS, et al. Among authors: patel mr. Clin Cancer Res. 2021 Apr 1;27(7):1864-1874. doi: 10.1158/1078-0432.CCR-20-3242. Epub 2021 Jan 25. Clin Cancer Res. 2021. PMID: 33495309 Clinical Trial.
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.
Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, Liang M, He P, Marshall S, Scheuber A, Das M, Patel MR. Pegram MD, et al. Among authors: patel mr. Mol Cancer Ther. 2021 Aug;20(8):1442-1453. doi: 10.1158/1535-7163.MCT-20-0014. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045233 Free PMC article. Clinical Trial.
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Saleh MN, et al. Among authors: patel mr. Clin Cancer Res. 2021 Oct 1;27(19):5236-5247. doi: 10.1158/1078-0432.CCR-21-0715. Clin Cancer Res. 2021. PMID: 34301750 Free PMC article. Clinical Trial.
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
Herrera AF, Patel MR, Burke JM, Advani R, Cheson BD, Sharman JP, Penuel E, Polson AG, Liao CD, Li C, Schuth E, Vaze A, Samineni D, Elstrom R, Cooper J, Diefenbach C. Herrera AF, et al. Among authors: patel mr. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. doi: 10.1158/1078-0432.CCR-21-3261. Clin Cancer Res. 2022. PMID: 34980599 Free PMC article. Clinical Trial.
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM. Meric-Bernstam F, et al. Among authors: patel mr. Clin Cancer Res. 2022 Apr 14;28(8):1540-1548. doi: 10.1158/1078-0432.CCR-21-2972. Clin Cancer Res. 2022. PMID: 35140121 Free PMC article. Clinical Trial.
1,265 results